Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

107.06 -2.03 (-1.86%)
Official Closing Price Updated: 7:00 PM EST, Nov 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,135,465
Open 106.81
Bid (Size) 106.72 (1)
Ask (Size) 107.20 (2)
Prev. Close 109.09
Today's Range 105.70 - 107.61
52wk Range 94.73 - 148.15
Shares Outstanding N/A
Dividend Yield 1.65%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its experimental obesity drug MariTide, while CNBC's Jim Cramer suggested the news could... 
Via Benzinga
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot
The company is testing MariTide as a monthly shot, rivaling weekly injections from Novo Nordisk and Eli Lilly. 
Via Investor's Business Daily

Performance

YTD
+4.85%
+4.85%
1 Month
-10.62%
-10.62%
3 Month
-19.85%
-19.85%
6 Month
-19.46%
-19.46%
1 Year
+6.23%
+6.23%

More News

Read More
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
Via Benzinga
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
Via Benzinga
Forecasting The Future: 7 Analyst Projections For Novo Nordisk
Via Benzinga
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,000 Today
Via Benzinga
Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?
Via The Motley Fool
Is Viking Therapeutics a Buy on the Dip?
Via The Motley Fool
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Via Benzinga
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
Via Investor's Business Daily
Topics Economy Government
Exposures Interest Rates Political
Investors Like Certainty. Trump's Win Gave Them Some.
Via The Motley Fool
Topics Government
Exposures Political
How Altimmune Could Grab a Big Chunk of the GLP-1 Market
Via MarketBeat
Smaller Cap Biotechs Are In Season: How Are We Doing?
Via Talk Markets
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
Via Benzinga
Topics Death
Exposures Death Product Safety
Novo Nordisk Aims For The Top: CagriSema Poised For Breakthrough
Via Talk Markets
Novo Nordisk (NVO) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast
Via Benzinga
Ozempic/Wegovy Maker Maintains Q3 Sales Growth On Booming Demand
Via Benzinga
Novo Nordisk Dips After Tightening Its Outlook As Wegovy Beats, But Ozempic Misses
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Via Benzinga
IBD 50's No. 2 Stock, Hims & Hers, Smashes Estimates On 'Robust' Obesity Trajectory
Via Investor's Business Daily
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
Via Benzinga
What's Going On With Hims & Hers Health Stock Monday?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.